職名 准教授
氏名 かとう ひでお
加藤 秀雄
生年月 1984.05
所属 部局 附属病院
学科・専攻 薬剤部
講座  
教育研究分野 臨床薬剤学
TEL 059-231-5420
FAX  
E-mail hkato59@med. (末尾に mie-u.ac.jp を補ってください)
個人のホームページ  
学歴 2008.03 岐阜薬科大学 薬学部 厚生薬学科 卒業
2010.03 岐阜薬科大学大学院 薬学研究科薬学専攻修士課程 修了
2018.03 愛知医科大学大学院 医学研究科博士課程 修了
学位 2018.03 博士(医学) 愛知医科大学大学院
所属学会 日本医療薬学会 日本化学療法学会 日本感染症学会
社会活動 International Journal of Environmental Research and Public Health, Topic Editor
Microorganisms, Reviewer Board
職歴 2010.04-2019.05 愛知医科大学病院 薬剤部 薬剤師
2018.04- 愛知医科大学 感染症科 研究員
2019.04-2021.01 The University of Queensland Centre for Clinical Research (UQCCR), Australia. Postdoctoral research fellow
2021.02- 三重大学医学部附属病院 薬剤部 准教授
学術(芸術)賞 2014.07 第5回MRSAフォーラム 優秀演題賞
2019.11 2019年度日本医療薬学会Postdoctoral Award
専門分野  
現在の研究課題  
担当科目  
主な業績等 1. Kato H, Hamada Y, Hagihara M, et al. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy. J Infect Chemother. 2015; 21:707-712.
2. Kato H, Hamada Y, Hagihara M, et al. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration. J Infect Chemother. 2016;22: 308-313.
3. Kato H, Hagihara M, Yamagishi Y, et al. Is dose adjustment based on several factors of body size descriptors effective for prevention of thrombocytopenia by linezolid therapy in hemodialysis patients? Pharmacology & Pharmacy. 2016; 7: 417-423.
4. Kato H, Hagihara M, Nishiyama N,et al. Clinical effectiveness of daptomycin loading dose in patients infected with Gram-positive pathogens. J Infect Chemother. 2017; 23: 161-164.
5. Kato H, Hagihara M, Nishiyama N, et al. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates. J Infect Chemother. 2017; 23: 154-160.
6. Kato H, Hagihara M, Sakanashi D, et al. Evaluation of amikacin pharmacokinetics with population pharmacokinetic analysis for optimal initial dosing regimen. Drugs R D. 2017; 17: 177-187.
7. Kato H, Hagihara M, Kato Y, et al. Adverse events of prophylactic anti-influenza agents in medical staffs. J Infect Chemother. 2017; 23: 683-686.
8. Kato H, Hagihara M, Murakami E, et al. Considerations about the use of a loading dose of daptomycin in neutropenic murine thigh infection model with methicillin-resistant Staphylococcus aureus infection. Chemotherapy. 2017; 63: 13-19.
9. Kato H, Hagihara M, Yamagishi Y, et al. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B. J Infect Chemother. 2018; 24: 725-728.
10. Kato H, Yamagishi Y, Hagihara M, et al. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria. J Infect Chemother. 2019; 25: 311-3.
11. Kato H, Hagihara M, Yokoyama Y, et al. Comparison of in vivo activities of garenoxacin and levofloxacin in a murine model of pneumonia by mixed-infection with Streptococcus pneumoniae and Parvimonas micra. Jpn J Infect Dis. 2019; 72: 407-12.
12. Kato H, Hagihara M, Shibata Y, et al. Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients. J Infect Chemother. 2020; 26: 215-224.
13. Kato H, Hagihara M, Asai N, et al. Meta-analysis of fluoroquinolones versus macrolides for treatment of Legionella pneumonia. J Infect Chemother. 2020; Accepted.
14. Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2020; Accepted.
15. Kato H, Parker SL, Roberts JA, et al. Population pharmacokinetics analysis of amikacin initial dosing regimen in elderly patients. Antibiotics (Basel). 2021; Accepted.

他、48報あり。